CNS

News

Regeneron and Alnylam announce $1bn collaboration

Regeneron has signed a collaboration deal potentially worth $1 billion with RNAi experts Alnylam Pharmaceuticals, to develop and commercialise drugs targeting eye, central nervous system (C

News

Pfizer’s CNS exit takes the form of a biotech spinout

Pfizer’s plans to duck out of central nervous system R&D have come to fruition, with the creation of spinout biotech Cerevel Therapeutics.

News

Closeup of X-ray photography of human brain

Tysabri failure in stroke a setback for Biogen

Biogen’s hopes that one of its established multiple sclerosis drugs might also help stroke sufferers have been dashed.

Views & Analysis

Social psychology concept as a group of connected network of people icons with one individual brain illuminated as a symbol for sociology and group interaction.

Looking back, looking forward – Janssen’s 60 years on the ps...

Improving targeted treatments and partnering on initiatives to reduce stigma and support mental health patients.

News

Ex-Novartis chief Epstein joins Remedy Pharmaceuticals

David Epstein, who left his job as head of Novartis’ pharma division in May, has joined Remedy Pharmaceuticals as a special advisor.

Regeneron and Alnylam announce $1bn collaboration

Pfizer’s CNS exit takes the form of a biotech spinout

Tysabri failure in stroke a setback for Biogen

Looking back, looking forward – Janssen’s 60 years on the ps...

Ex-Novartis chief Epstein joins Remedy Pharmaceuticals

LSX2026: Addressing adult eye cancer, with Roi Raz

Using AI-driven synthetic personas to take your insights fur...

CNS

Editor's Picks